CN105164536B - 阿尔兹海默症诊断的组合物和方法 - Google Patents

阿尔兹海默症诊断的组合物和方法 Download PDF

Info

Publication number
CN105164536B
CN105164536B CN201480008554.4A CN201480008554A CN105164536B CN 105164536 B CN105164536 B CN 105164536B CN 201480008554 A CN201480008554 A CN 201480008554A CN 105164536 B CN105164536 B CN 105164536B
Authority
CN
China
Prior art keywords
complement
alpha
protein
afamin
antichymotrypsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480008554.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105164536A (zh
Inventor
彼得·菲茨杰拉德
伊凡·麦康内尔
约翰·拉蒙特
夏兰·理查德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Randox Teoranta
Original Assignee
Randox Teoranta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Randox Teoranta filed Critical Randox Teoranta
Publication of CN105164536A publication Critical patent/CN105164536A/zh
Application granted granted Critical
Publication of CN105164536B publication Critical patent/CN105164536B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Databases & Information Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Computation (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Epidemiology (AREA)
  • Software Systems (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioethics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
CN201480008554.4A 2013-03-05 2014-03-04 阿尔兹海默症诊断的组合物和方法 Active CN105164536B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1303936.7 2013-03-05
GB1303936.7A GB2511525A (en) 2013-03-05 2013-03-05 Methods and Compositions for the Diagnosis of Alzheimer's Disease
PCT/EP2014/054185 WO2014135546A1 (en) 2013-03-05 2014-03-04 Methods and compositions for the diagnosis of alzheimer's disease

Publications (2)

Publication Number Publication Date
CN105164536A CN105164536A (zh) 2015-12-16
CN105164536B true CN105164536B (zh) 2018-02-06

Family

ID=48142456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480008554.4A Active CN105164536B (zh) 2013-03-05 2014-03-04 阿尔兹海默症诊断的组合物和方法

Country Status (9)

Country Link
US (1) US20160097780A1 (enExample)
EP (1) EP2965090B1 (enExample)
JP (1) JP6430413B2 (enExample)
CN (1) CN105164536B (enExample)
AU (1) AU2014224727B2 (enExample)
CA (1) CA2900002C (enExample)
ES (1) ES2674526T3 (enExample)
GB (1) GB2511525A (enExample)
WO (1) WO2014135546A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504432D0 (en) * 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
JP6702836B2 (ja) * 2016-09-28 2020-06-03 ハルメク・ベンチャーズ株式会社 認知症判定得点算出装置及びそのプログラム
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
WO2019086555A1 (en) * 2017-10-31 2019-05-09 Ge Healthcare Limited Medical system for diagnosing cognitive disease pathology and/or outcome
JP6950952B2 (ja) * 2017-12-20 2021-10-13 国立大学法人三重大学 脳アミロイド血管症の末梢血バイオマーカー
CN108681748A (zh) * 2018-05-18 2018-10-19 宝枫生物科技（北京）有限公司 判别轻度认知障碍的模型选择处理方法及装置
BR112021000895A2 (pt) * 2018-07-19 2021-04-13 Genentech, Inc. Métodos para identificar um indivíduo como possuindo ou estando em risco de desenvolver uma demência positiva para amilóide e para detectar um indivíduo com um valor aumentado para uma combinação de marcadores e uso de ass40, ass42 e ttau
CN110464833A (zh) * 2019-09-04 2019-11-19 北京豪思生物科技有限公司 铜蓝蛋白的应用
WO2021071219A1 (ko) * 2019-10-07 2021-04-15 조한나 퇴행성 신경질환의 진단용 바이오마커
JP7109499B2 (ja) * 2020-05-07 2022-07-29 一般社団法人脳と心の健康科学研究所 認知症判定得点算出装置及びそのプログラム
US20240077501A1 (en) * 2020-12-28 2024-03-07 Mcbi Inc. Judgment supporting information generating method, judgment supporting information generating system, and information processing device
ES2924776A1 (es) * 2021-03-25 2022-10-10 Univ Castilla La Mancha Metodos para el diagnostico y pronostico de la enfermedad de alzheimer
CN112858697B (zh) * 2021-03-29 2024-03-01 鲁东大学 ALG-2-interacting protein X在制备分子标志物中的应用
CN114634970A (zh) * 2022-03-29 2022-06-17 南通惠皓医疗科技有限公司 遗传性阿尔兹海默症致病基因panel检测方法
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用
CN118475840A (zh) * 2022-06-28 2024-08-09 株式会社Mcbi 判定辅助信息生成方法、判定辅助信息生成系统以及信息处理装置
CN116063447B (zh) * 2022-09-13 2023-11-03 北京湃德智健科技有限公司 用于检测adap自身抗体的抗原多肽及其应用
CN119495355A (zh) * 2024-10-31 2025-02-21 山东大学 一种阿尔兹海默症诊断标志物的筛选方法和系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235718A1 (en) * 2001-04-30 2004-11-25 Michael Becker-Andre Afamin-containing compositions methods of use
US20070099203A1 (en) * 2005-10-27 2007-05-03 Jing Zhang Biomarkers for neurodegenerative disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH067191A (ja) * 1991-09-26 1994-01-18 Konica Corp モノクローナル抗体、それを産生するハイブリド−マ、その対応抗原及びそれを用いた測定方法
US5652352A (en) * 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene
DE60225821T2 (de) * 2001-10-04 2009-04-30 Immuno-Biological Laboratories Co., Ltd., Takasaki Reagens zum Nachweis eines Risikofaktors der Alzheimer-Krankheit, Nachweiskit dafür und Verfahren zum Nachweis eines Risikofaktors der Alzheimer-Krankheit unter ihrer Verwendung
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2006108051A2 (en) * 2005-04-05 2006-10-12 Neurodx, Llc Compositions and methods relating to alzheimer's disease
GB0512401D0 (en) * 2005-06-17 2005-07-27 Randox Lab Ltd Method
AT505727B1 (de) * 2007-09-04 2009-06-15 Univ Innsbruck Verfahren zur diagnose des metabolischen syndroms
GB0921447D0 (en) * 2009-12-04 2010-01-20 Randox Lab Ltd Assay
EP2569451A4 (en) * 2010-05-14 2013-09-11 Rules Based Medicine Inc METHOD AND DEVICES FOR DIAGNOSING MORBUS ALZHEIMER
US20150010914A1 (en) * 2012-01-20 2015-01-08 Adelaide Research & Innovation Pty Ltd. Biomarkers for gastric cancer and uses thereof
ITMI20120865A1 (it) * 2012-05-18 2013-11-19 Antonio Bertolotto Biomarcatori per patologie del sistema nervoso centrale

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235718A1 (en) * 2001-04-30 2004-11-25 Michael Becker-Andre Afamin-containing compositions methods of use
US20070099203A1 (en) * 2005-10-27 2007-05-03 Jing Zhang Biomarkers for neurodegenerative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Afamin Is a Novel Human Vitamin E-Binding Glycoprotein Characterization and In Vitro Expression;Lidija Jerkovic et al;《JOURNAL OF PROTEOME RESEARCH》;20050501;第4卷(第3期);第892页 *

Also Published As

Publication number Publication date
CA2900002A1 (en) 2014-09-12
CA2900002C (en) 2022-01-25
GB201303936D0 (en) 2013-04-17
JP6430413B2 (ja) 2018-11-28
WO2014135546A1 (en) 2014-09-12
US20160097780A1 (en) 2016-04-07
EP2965090B1 (en) 2018-04-25
CN105164536A (zh) 2015-12-16
AU2014224727A1 (en) 2015-08-13
JP2016511406A (ja) 2016-04-14
ES2674526T3 (es) 2018-07-02
AU2014224727B2 (en) 2020-09-03
EP2965090A1 (en) 2016-01-13
GB2511525A (en) 2014-09-10

Similar Documents

Publication Publication Date Title
CN105164536B (zh) 阿尔兹海默症诊断的组合物和方法
Ottervald et al. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers
TWI788704B (zh) 分析個體樣品之方法
CN103827671B (zh) 用于检测神经疾病的方法
US20120178637A1 (en) Biomarkers and methods for detecting alzheimer's disease
CN102762986B (zh) 阿尔茨海默病的诊断方法
WO2011143574A2 (en) Plasma biomarkers for diagnosis of alzheimer's disease
CN112567246A (zh) 治疗脊髓性肌萎缩症的方法
JP6440719B2 (ja) 腎疾患のバイオマーカー
Jang et al. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease
US20190113527A1 (en) Assay for the diagnosis of a neurological disease
US10078089B2 (en) Compositions and methods for treating steroid resistant nephrotic syndrome and/or steroid sensitive nephrotic syndrome
US20150293120A1 (en) Marker sequences for rheumatoid arthritis
CN113358881B (zh) 用于nmosd预测或复发监测的生物标志物及其应用
JP6252949B2 (ja) 統合失調症マーカーセット及びその利用
KR102254053B1 (ko) 인지기능 정상군 또는 경도 인지장애에서 아밀로이드 베타의 뇌 침착 검출용 혈액 바이오 마커
CA3062763A1 (en) Diagnostic biomarkers for detecting, subtyping, and/or assessing progression of multiple sclerosis
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
US20170176434A1 (en) Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis
Chenling Biomarker Panel Array Systems for Disease Detection
CN119120680A (zh) Zcchc2在干燥综合征诊断与区分系统性红斑狼疮中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant